Giessen

• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma
• A study to evaluate the efficacy and safety of treatment with JR-141 Ended recruitment
  2024-512289-33-00 5 2022-08-24 Mucopolysaccharidosis type II
• A Clinical Study of Lazertinib with Subcutaneous Amivantamab Compared with Intravenous Amivantamab in Patients with EGFR-mutated Advanced or … Ended recruitment
  2024-512045-16-00 5 2022-08-18 EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
• Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) Ended recruitment
  2022-503028-29-01 4 2021-12-14 Patients with stage IV EGFR-mutation positive NSCLC target population
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati … Ended recruitment
  2023-507342-84-00 5 2021-10-26 Bladder Cancer
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun … Ended recruitment
  2023-507494-18-00 5 2021-09-24 Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosin
• Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung … Ended recruitment
  2024-513770-22-00 4 2021-09-22 Malignant Solid Tumors - Non Small Cell Lung Cancer
• "Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)" Ended recruitment
  2024-516754-22-00 4 2021-07-14 Pulmonary Arterial Hypertension (PAH)
• Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen … Ended recruitment
  2023-505637-27-00 5 2021-07-12 Spinal Muscular Atrophy
• DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended recruitment
  2023-509865-19-00 5 2021-04-30 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended recruitment
  2024-513433-20-00 4 2020-12-16 Limited Disease Small Cell Lung Cancer
• Long-term need of Ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due … Ended recruitment
  2023-507816-11-00 5 2020-08-17 Macular edema due to central retinal vein occlusion
• Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratifica … Ended recruitment
  2023-509394-23-00 5 2020-06-12 Stage II melanoma arising from a primary cutaneous site after surgery
• ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty … Ended recruitment
  2024-513947-94-00 4 2020-03-30 locally advanced (stage III) and not suitable for curative treatment,
• Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined … Ended recruitment
  2024-511577-29-01 5 2020-03-13 intermediate and high-risk rectal cancer
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemop … Ended recruitment
  2022-502844-11-00 5 2020-01-29 severe to moderately severe hemophilia B (FIX:C ≤ 2%)
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended recruitment
  2023-504821-38-00 4 2019-09-19 Classical Hodgkin lymphoma in children and young adults
• Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno … Ended recruitment
  2023-503670-21-00 5 2019-08-28 Patients with newly diagnosed AML and intermediate- or adverse-risk ge
• Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended recruitment
  2023-507582-25-00 5 2019-08-02 Malignant Extracranial Germ Cell Tumours (MGCT)
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma

Showing 169–192 of 243 trials